Press Releases

Press Releases

INDI® ANNOUNCES EARLY DATA SUPPORTING XPRESYS® LUNG TO BE PRESENTED AT ATS 2014

SEATTLE, April 29, 2014 – Indi (Integrated Diagnostics), a molecular diagnostics company pioneering the use of blood-based proteomic tests, announced today that preliminary data supporting Xpresys Lung – and characterizing decision-making in the management of lung nodules – will be presented at the American Thoracic Society (ATS) 2014 International Conference taking place May 16-21, 2014 in San Diego. Xpresys Lung, which was first marketed in October 2013, is a breakthrough molecular diagnostic blood test developed to provide physicians with an objective, non-invasive tool to address a major medical dilemma—the management of indeterminate lung nodules.

“We are pleased to add to the growing body of data that help clinicians better diagnose indeterminate lung nodules,” said Albert A. Luderer, Ph.D., chief executive officer, Indi. “Xpresys Lung was designed to help physicians diagnose more lung nodules as likely benign—increasing the share of patients who can confidently choose serial CT scans of their nodules instead of invasive procedures like surgery and biopsy, that carry significant risks and costs. These data will give physicians greater insight into how the test can help them to better diagnose their patients.”

The following abstract will be shared as part of "A View to the Lung: Lung Cancer Screening and the Evaluation of Pulmonary Nodules,” a poster discussion session at the ATS Conference:

Title: A Markov Model Derived To Quantify Drivers Of Decision Making In The Evaluation Of Patients With Pulmonary Nodules
Presenter: Anil Vachani, M.D.
Time: Sunday, May 18, 2014, 2:00 - 4:30 p.m.
Location: Hilton San Diego Bayfront, Indigo Ballroom E (Level 2)

The following two abstracts will be shared as part of "Golden Eye: Screening and Risk Prediction for Lung Cancer,” a mini-symposium at the ATS Conference:

Title: The Potential Impact Of A Non-Invasive Diagnostic Test On Clinical Decision-Making For Indeterminate Pulmonary Nodules
Presenter: Anil Vachani, M.D.
Time: Wednesday, May 21, 2014, 2:00 - 4:30 p.m.
Location: Hilton San Diego Bayfront, Indigo Ballroom D/H (Level 2)

Title: Clinical Validation Of A Plasma Proteomic Classifier To Identify Benign Lung Nodules
Presenter: Pierre Pascal Massion, M.D.
Time: Wednesday, May 21, 2014, 2:00 - 4:30 p.m.
Location: Hilton San Diego Bayfront, Indigo Ballroom D/H (Level 2)

About Indi

Indi (Integrated Diagnostics) is redefining molecular diagnostics and creating powerful new tools for physicians to non-invasively assess and more effectively manage complex diseases to improve patient outcomes, reduce complications, and lessen costs to the healthcare system. With the company’s first breakthrough test, Xpresys Lung, which measures multiple blood proteins and identifies lung nodules with a high probability of being benign, physicians have the potential to reduce risks and the need for unnecessary invasive procedures.

The company was co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, who recently received the National Medal of Science from the U.S. government. His groundbreaking research is based on a systems biology approach, which measures hundreds of protein biomarkers found in blood to report on the physiological state of the body’s 50 major organs, such as the lungs.

Backers include Baird Capital, InterWest Partners, Life Sciences Alternative Financing and the Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com

 
 
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue